期刊論文1. | Owen, David G.(2010)。Dangers in Prescription Drugs : Filling A Private Law Gap in the Healthcare Debate。CONN. L. REV,42,733。 |
2. | 楊秀儀(20070600)。論病人自主權--我國法上「告知後同意」之請求權基礎探討。國立臺灣大學法學論叢,36(2),229-268。 延伸查詢 |
3. | 陳聰富(20090100)。醫療侵權之歸責原則。月旦法學教室,75,81-92。 延伸查詢 |
4. | 曾育裕(20050800)。醫療事故民事責任之演進與發展。東吳法律學報,17(1),115-150。 延伸查詢 |
5. | 侯英泠(20080600)。醫療機構、外科醫師與麻醉科醫師之說明義務--最高法院九六年臺上字第二四七六號判決簡評。臺灣法學雜誌,107,291-297。 延伸查詢 |
6. | 陳忠五(20051100)。產前遺傳診斷失誤的損害賠償責任--從「新光醫院唐氏症事件」論我國民事責任法的新課題。國立臺灣大學法學論叢,34(6),107-260。 延伸查詢 |
7. | 楊秀儀(20021000)。論醫療糾紛之定義、成因及歸責原則。臺灣本土法學雜誌,39,121-131。 延伸查詢 |
8. | 陳聰富(20090800)。告知後同意與醫師說明義務。月旦法學教室,82,66-80。 延伸查詢 |
9. | 陳聰富(20040700)。論侵權行為法上之過失概念--最高法院九十年度臺上字第一六八二號民事判決評釋。國立臺灣大學法學論叢,33(4),145-204。 延伸查詢 |
10. | 汪紹銘(2007)。藥品仿單外之使用(Off-Label Use)之法律問題。全國律師,11(12),73-81。 延伸查詢 |
11. | 曾品傑(2010)。我國醫療民事責任之實務發展-兼論法國法對於我國實務之啟發。國立中正大學法學集刊,29,69-135。 延伸查詢 |
12. | Ausness, Richard C.(2008)。“There’s Danger Here, Cherie!”: Liability for the Promotion and Marketing of Drugs and Medical Devices for Off-Label Uses。BROOK. L. REV.,73,1253。 |
13. | Atwell, Barbara L.(2006)。The Modern Age of Informed Consent。U. RICH. L. REV.,40,591。 |
14. | Beck, James M.、Azari, Elizabeth D.(1998)。FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions。FOOD & DRUG L.J.,53,71。 |
15. | Coutinho, Santosh V.(2009)。License to Promote, or Just What the Doctor Ordered? the New FDA Guidance on Dissemination of Off-label Reprints by Pharmaceutical Companies。TEMP. J. SCI. TECH. & ENVTL. L.,28,279。 |
16. | Girod, Jennifer(2007)。The Learned Intermediary Doctrine: An Efficient Protection for Patients, Past and Present。IND. L. REV.,40,397。 |
17. | Grant, Jonathan E.(1988)。The “Misuse” Defense in Drug Products Liability Cases。PACE L. REV.,8,535。 |
18. | Johns, Margaret Z.(2007)。Informed Consent: Requiring Doctors to Disclose Off-Label Prescriptions and Conflicts of Interest。HASTINGS L.J.,58,967。 |
19. | Ketler, Suzanne K.(2001)。The Rebirth of Informed Consent: A Cultural Analysis of the Informed Consent Doctrine After Schreiber v. Physicians Insurance Co. of Wisconsin。NW. U. L. REV.,95,1029。 |
20. | Kurtz, Sheldon F.(2000)。The Law of Informed Consent: From “Doctor Is Right” to “Patient has Rights”。SYRACUSE L. REV.,50,1243。 |
21. | Miller, Kate(2005)。Hormone Replacement Therapy in the Wake of the Women's Health Initiative Study: An Opportunity to Reexamine the Learned Intermediary Doctrine。WM. & MARY J. WOMEN & L.,12,239。 |
22. | Noah, Lars(2009)。Symposium: The Products Liability Restatement: Was It a Success? This Is Your Products Liability Restatement Drugs。BROOK. L. REV,74,839。 |
23. | Osborn, John E.(2010)。Can I Tell You the Truth? A Comparative Perspective on Regulating Offlabel Scientific and Medical Information。YALE J. HEALTH POL’Y, L. & ETHICS,10,299。 |
24. | Owen, David G.(2000)。Products Liability: User Misconduct Defenses。S.C. L. REV.,52,1。 |
25. | Salbu, Steven R.(1999)。Off-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy。FLA. L. REV.,51,181。 |
26. | Shifton, Mark D.(2002)。The Restatement (Third) of Torts: Products Liability-The Ali's Cure for Prescription Drug Design Liability。FORDHAM URB. L.J.,29,2343。 |
27. | Stoffelmayr, Kaspar J.(1996)。Products Liability and “Off-Label” Uses of Prescription Drugs。U. CHI. L. REV.,63,275。 |
28. | Studer, Martin R.(1987)。The Doctrine of Informed Consent: Protecting the Patient’s Right to Make Informed Health Care Decisions。MONT. L. REV.,48,85。 |